Chemcon-Specialty-Chemicals-Limited.

Chemcon Specialty Chemicals manufacture specialized chemicals, such as HMDS and CMIC which are predominantly used in the pharmaceuticals industry and inorganic bromides, namely Calcium Bromide, Zinc Bromide and Sodium Bromide, which are predominantly used as completion fluids in the oilfields. Company is the only manufacturer of HMDS in India and was the third largest manufacturer of HMDS worldwide in terms of production in the calendar year 2019.

Chemcon Specialty Chemicals Limited IPO

Wants To Apply Online

Chemcon-Specialty-Chemicals-Limited

Issue Details
Objects of the issue ·        Capital expenditure towards expansion

of Manufacturing Facility;

·        To meet working capital requirements;

And,

·        General corporate purposes

 

 

 

Issue Size Issue Size : Rs. 318 Crore

Offer for Sale – Rs. 153 crore

Fresh Issue  – 165 Crore

Face value  

Rs.10 Per Equity Share

Issue Price Rs. 338 – Rs. 340
Bid Lot 44 shares
Listing at  

NSE, BSE

Issue Opens: 21st September 2020 – 23rd  September 2020
QIB 50% of Net Issue Offer
NIB 15% of Net Issue Offer
Retail 35% of Net Issue Offer

Financial Performance:

Financial-Performance

Elite-Kuber-App-Mutual-Fund-Promotional-Banner-img2

Shareholding Pattern:

Shareholding Pattern Pre- Issue Post Issue
Promoters & Promoters Group 100% 74.47%
Public& Others 25.53%


Source: DRHP, EWAL Research

Elite-Empower-App-Promotional-Banner-img1

Strengths:

  • Leading manufacturer globally of the Pharmaceutical Chemicals and a leading manufacturer in India of the Oilwell Completion Chemicals.

  • Diversified customer base coupled with long standing relationship

  • Consistent financial performance with a strong financial position

Key Highlights:

  • For Fiscals 2020, 2019 and 2018, revenue from operations was ₹ 2,620.52 million, ₹3,033.41 million and ₹1,576.42 million, respectively, growing at a CAGR of 28.93% between Fiscal 2018 and Fiscal 2020.

  • In Fiscals 2020, 2019 and 2018, Pharmaceutical Chemicals, contributed 63.75%, 63.14% and 62.18% of total revenue from operations respectively, while Oilwell Completion Chemicals, contributed 33.47%, 35.30% and 35.63% respectively of total revenue from operations.

  • The key customers of Pharmaceutical Chemicals include Hetero Labs Limited, Laurus Labs Limited, Aurobindo Pharma Limited, Sanjay Chemicals (India) Private Limited, Lantech Pharmaceuticals.

  • Key customers of Oilwell Completion Chemicals include Shree Radha Overseas, Water Systems Specialty Chemical DMCC and CC Gran Limited Liability Company.

Risk Factors:

  • Naresh Vijaykumar Goyal, a member of Promoter Group, has filed an appeal in relation to a criminal proceeding filed against him, which if determined adversely may have a negative impact on company operations, reputation and prospects.

  • The company has a limited product portfolio and business may be adversely affected if any of products do not continue to perform as expected

  • If Competitors are able to improve the efficiency of their manufacturing processes and thereby offer their products at lower prices, revenues and profitability of the company may decline.

Outlook:

Chemcon Chemical is India’s largest manufacturer of specialised chemicals, such as Hexamethyldisilazane (HMDS) and Chloromethyl Isopropyl Carbonate (CMIC), which are predominantly used in the pharmaceuticals industry. Chemcon supplies its products to domestic customers and also exports to countries including USA, Italy, South Korea, Germany, China, and Japan. As of July 31, 2020, the installed capacity for HMDS was 4,200 MT per annum and HMDS (hi-purity) was 600 MT per annum. India is a net importer of CMIC and HMDS and the company aims to expand manufacturing and sales operations of CMIC and HMDS to substitute such imports. At the higher end of the price band of Rs. 340, the stock will be available at a PE multiple of 22.1x on FY20 EPS. Considering less impacted business model of the company in COVID-19 we would recommend subscribe to this IPO.


 DISCLOSURE IN PURSUANCE OF SECTION 19 OF SEBI (RA) REGULATION 2014

Elite Wealth Advisors Limited does/does not do business with companies covered in its research reports. Investors should be aware that the Elite Wealth Advisors Limited may/may not have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as read more


For Daily Share Market Updates, Daily debt market review, Market Research Analysis reports, Weekly Techno-Funda Report, Fundamental Analysis Report, Monthly Recommended stock Picks, Equity Trading Tips, Upcoming IPO/NFO/Bonds/Ncd’s  updates & other related information Subscribe our research plan